All News
Serum calprotectin: a better biomarker in ANCA-associated vasculitis?
Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.
How do you approach your PsA patients with suboptimal response to MTX in moderate doses?
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC
Olga Petryna DrPetryna ( View Tweet)
#eular2020 #op0205 phase 1 trial of novel URAT1 inhibitor D-0120 in healthy adults: safe up to 20 mg/d after 7 days. Significant reduction of sUA peaks at 4-8h & lasts up to 24h @RheumNow
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT 52wk study. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID. MRI BME score significantly decreased (-1.68&-1.03 (no LD) vs -0.39 PBO) @RheumNow https://t.co/UX7mkJ8qMJ
Olga Petryna DrPetryna ( View Tweet)
#eular2020 #op0227 52 wk SEC vs ADA H2H EXCEED trial: Acr20 67.4%SEC vs 61.5%ADA. Better retention of SEC at 85.7% vs 76.3%ADA. SEC significantly outperforms in PASI90 (65.4 SEC be 43.2 ADA) @RheumNow https://t.co/M8UGydTFDF
Olga Petryna DrPetryna ( View Tweet)
EULAR2020 #op0168 🇰🇷Population-based cohort study identifies both allopurinol& febuxostat associated with MI, cerebral infarction&cerebral hemorrhage. Fluctuation of sUA&potentially even cardiovascular gout attacks (urate crystals in vasculature) as possible causes @RheumNow https://t.co/mcb5NLnMq1
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0028 12 wk ph3 RELIEF study: Apremilast effectively relieves OU pain and OU number after 12 wks of 30 mg bid Rx. Great proportion of APR PTs achieved >10 mm &>30 mm improvement in OU pain @RheumNow https://t.co/p71sz9XL0e
Olga Petryna DrPetryna ( View Tweet)
Lots of talk about best bDMARDs in RA-ILD, but what about in RA-assoc bronchiectasis?
@Yuz6Yusof found rituximab had better 'lung survival' vs TNFi (similar baseline stats)
Something to consider in these difficult-to-treat pts?
@LeedsBRC Newcastle THU0143 #EULAR2020 @RheumNow https://t.co/XpffkDNqhU
David Liew drdavidliew ( View Tweet)
For patients on bDMARDs having surgery, we worry about post-op delayed wound healing.
In this Japanese cohort, TCZ use was a risk factor.
Unclear if meds withheld, but given IL-6 upreg in wound healing, it's plausible TCZ might have worse outcomes??
SAT0047 #EULAR2020 @RheumNow https://t.co/HVIKPplwiA
David Liew drdavidliew ( View Tweet)
So maybe the optimal dose for psoriasis with UPA in PsA was tested? UPA works in PsA so another potential Rx for pts LB0001 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/GiT7H91umA
Janet Pope Janetbirdope ( View Tweet)
Whom with GCA should receive tocilizumab? What happens when it is stopped? Optimal dose for maintenance weekly or Q2 weekly? GiACTA gives only some answers. Need RWE #EULAR2020 @eular_org @RheumNow @CRASCRRheum @earlyarthritis #vasculitis https://t.co/aNvR14vfEV
Janet Pope Janetbirdope ( View Tweet)
What dose/frequency of rituximab do you use in maintenance ANCA #vasculitis? @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020
Janet Pope Janetbirdope ( View Tweet)
Hand OA Rx strikes out. HCQ Rx neg and colchicine Trial negative. I wouldn’t put hand OA as same category of no Rx as for SSc and Sjogrens but agree though nuts to crack @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/QRe3UpKpbz
Janet Pope Janetbirdope ( View Tweet)
Awesome colchicine data from @CatherineL_Hill @samwhittle and others: Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH) Abstract FRI0399 #EULAR2020 @RheumNow https://t.co/NVw9fo55dc https://t.co/LfHZVQTwIf
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
#EULAR2020 THU0260 LESS IS BEST when it comes to steroids: Singapore 10 yr retrospect SLE study noted GCs dose is an independent predictor of mortality for hospitalized infection even when adjusted for disease activity.
k dao KDAO2011 ( View Tweet)
#tacrolimus #prograf is non inferior to #MMF #cellcept in #lupus #nephritis induction. We’ve been doing it for years but great to see some solid RCT data behind this. #rheumatology #SLE #autoimmune https://t.co/CblD4GaXCp
Mohammad A. Ursani MD, RhMSUS DrMAUrsani ( View Tweet)
#EULAR2020 Dr. V Ritschl:EULAR Task Force on Patient Adherance: 30-80% of pts do not adhere to Rx. resulting in ⬆️dz severity, pain, fatigue, depression, decreased in function, physical activity. HCPs should discuss adherance reg. & explore factors affecting adherance. @RheumNow
k dao KDAO2011 ( View Tweet)
